Nature bypasses profit forecast; Stuttering in income – the capital market

0
9



The Israeli pharmaceutical giant


nature
+3.89%






nature


Base:4,118

opening:4,059

Tall:4,287

low:4,053

change:51,780,150

Page Quote News Graphs Company Profile Recommendations


More articles on the subject:




Which is also traded on Wall Street (NYSE: TEVA) surpasses analysts’ expectations for the second quarter of 2020.

Teva’s revenues in the second quarter of 2020 amounted to $ 3.9 billion, compared to revenues of about $ 4.34 billion in the corresponding quarter last year. Analysts expected revenue of about $ 3.93 billion.

On the bottom line, Teva reports adjusted earnings (Non-GAAP) of 55 cents per share, compared to earnings of 60 cents per share in the corresponding quarter last year. Analysts had expected adjusted earnings of 53 cents a share.

Join

To

ad

Advertisement



Forecasts for 2020
For the year 2020 as a whole, Teva confirms its forecasts, with expected revenues in the range of $ 16.6-17 billion, EBITDA in the range of $ 4.5-4.9 billion and earnings per share in the range of $ 2.3-2.55. Free cash flow (FCF) is expected to be in the range of $ 1.8-2.2 billion.

Revenue Segmentation – Revenue from Ostedo and Copaxone is well above expectations

Generic unit revenue totaled about $ 923 million, slightly above analysts’ revenue expectations of $ 918 million. Ajobi sales were in line with forecasts – $ 34 million. Ousto sales totaled $ 161 million – well above expectations for sales of $ 135 million, and in Copaxone sales were well above expectations and totaled $ 238 million, compared to expectations for sales of $ 178 million.

Cash flow from operating activities for the quarter amounted to $ 273 million, compared with $ 227 million for the corresponding quarter.

The amount of net financial debt amounted to about $ 23.9 billion. Gross debt amounted to approximately $ 26.3 billion, compared to approximately $ 26.1 billion at the end of the first quarter.

Carr Schultz, President and CEO of Teva: “As the Corona virus continues to have an impact on the world, Teva remains focused on our patients and the communities we serve while continuing to keep our employees safe. Over the past quarter we have seen lower generic and over-the-counter sales in all regions. Low sales in Europe and international markets One of the expectations, after the unusually high demand in the previous quarter, was the initial response to the outbreak of the epidemic. However, our performance in the first half of the year stood and even exceeded the corresponding period last year. Our profitability, and especially free cash flow, was strong We must continue to reduce net debt to $ 23.9 billion and approve the annual forecast for 2020. “

Schultz went on to say, “During the quarter we made progress with most of our growth engines, including the launch of the AJOVY auto syringe in the US, the continued launch of AJOVY in Europe, the launch of the US biosimilar drug TRUXIMA for rheumatoid arthritis, and the approval of AUSTEDO in addition. , We recently announced the launch of ProAir DigiHaler in the US and an application for the production and marketing of AJOVY in Japan. Looking ahead to the second half of 2020, we continue to be committed to serving the world and our stakeholders with vital and affordable drugs and ensuring that Teva meets its goals. ”

Comments on the article(3):

Your response has been received and will be published subject to system policies.
Thanks.

For a new response

Your response was not sent due to a communication problem, please try again.

Return to comment

  • 3.

    It should go down by a good few percent (LT)

    LOL
    05/08/2020
    14:43

    0

    1

  • 2.

    Nature returns in a big way

    Edward
    05/08/2020
    14:36

    1

    0

    Funny gate right now. Another year 70%

    closed

  • 1.

    It’s good to focus on profit

    dw
    05/08/2020
    14:32

    0

    0

    I prefer to sell less drugs but ones that profit from them instead of selling chicken in shekels and subsidizing customers all over the world. Notice the nice growth of the osteo product, which starts to smell like the Copaxone product. Not bad. Hopefully the Ajubi will also climb to these levels and even more. $ 2.5 per share of $ 12.5 is a multiplier of 5. Not bad. Maybe Warren Buffett would like to increase his position on paper a bit?

    closed

LEAVE A REPLY

Please enter your comment!
Please enter your name here